|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis显示文摘Although the current standard treatment for hepatocellular carcinoma(HCC) with portal vein tumor thrombosis(PVTT) is sorafenib, many previous studies have established the need for a reliable local modality for PVTT control, which is a major cause of liver function deterioration and metastasis. Additionally, there is growing evidence for the prognostic significance of PVTT classification according to the location of tumor thrombosis. Favorable outcomes can be obtained by applying local modalities, including surgery or transarterial chemoembolization, especially in second-order or distal branch PVTT. Rapid control of PVTT could maintain or improve liver function and reduce intrahepatic as well as distant metastasis. Radiotherapy(RT) is one of the main locoregional treatment modalities in oncologic fields, but has rarely been used in HCC because of concerns regarding hepatic toxicity. However, with the development of advanced techniques, RT has been increasingly applied in HCC management. Randomized studies have yet to definitively prove the benefit of RT, but several comparative studies have justified the application of RT in HCC. The value of RT is especially noticeable in HCC with PVTT; several prospective and retrospective studies have reported favorable outcomes, including a 40% to 60% objective response rate and median overall survival of 15 mo to 20 mo in responders. In this review, we evaluate the role of RT as an alternative local modality in HCC with PVTT. | Jeong Il Yu Hee Chul Park | 2016 | World Journal of Gastroenterology2016，22，30： | 20 |
| 2 | 立体定向放射治疗技术在肝癌中的应用及进展显示文摘原发性肝癌是世界范围内的常见肿瘤之一,发病率居第7,而致死率位居第3[1]。在我国,肝癌的问题尤为严重,发病率位居第4,死亡率位居第3[2]。其中肝细胞肝癌(Hepatocellular Carcinoma,HCC)占85%~90%以上。 | 刘文扬 金晶 | 2019 | 肝癌电子杂志2019，6，1： | 3 |
| 3 | 射波刀与大分割三维适形放疗治疗原发性肝癌的疗效比较显示文摘目的比较大分割三维适形放疗(3D conformal radiotherapy,3DCRT)与射波刀(cyberknife,CK)治疗原发性肝癌的临床疗效和不良反应。方法回顾分析济南军区总医院放疗科2013年6月-2015年6月行大分割3DCRT及CK治疗的原发性肝癌患者资料,其中CK治疗组30例,3DCRT组39例,两组患者基线资料具有可比性,CK组36~50 Gy/2~5 f,1次/d,3DCRT组31.5~66 Gy/7~19 f,1次/d或隔日1次。结果随访时间为6~30个月,随访率95.65%。CK组、3DCRT组近期有效率分别为73.33%、64.10%(P=0.606),1年生存率分别为70.84%、56.67%(P=0.473),不良反应发生率分别为16.67%、41.03%(P=0.029),肝功能下降分别为2例、9例,放射性肝炎分别为0例、2例。结论射波刀较大分割三维适形治疗原发性肝癌有一定的局部控制优势及生存优势,但不明显,不良反应相对较小。 | 张秋琪 汪延明 | 2016 | 解放军医学院学报2016，37，8： | 3 |
| 4 | 对比立体定向放射治疗与射频消融治疗肝细胞癌效果的Meta分析显示文摘目的全面收集国内外立体定向放射治疗(SBRT)和射频消融(RFA)治疗肝细胞癌(HCC)相关研究文献,通过Meta分析系统比较这两种治疗方法的临床效果及相关并发症。方法计算机检索PubMed、Embase、Cochrane Library、Scopus、Web of Science以及中国生物医学文献(CBM)、知网、万方、维普等中英文数据库自建库至2022年6月发表的SBRT和RFA临床治疗HCC文献。采用Stata 14.0软件进行Meta分析。结果共纳入14项回顾性研究6806例患者。基于总生存期(OS)的综合风险比(HR)结果显示SBRT术后OS低于RFA术后(HR=1.25,95%CI=1.10~1.43,I^(2)=0%,P=0.0009),而局部控制(LC)比率的综合HR显示SBRT有更好的疗效(HR=0.61,95%CI=0.47~0.78,I^(2)=0%,P=0.0001)。亚组分析显示,LC比率的综合HR更支持对肿瘤直径>2 cm患者行SBRT(HR=2.64,95%CI=1.56~4.48,I^(2)=0%,P=0.0003)。SBRT组与RFA组间晚期严重不良反应发生率差异无统计学意义(OR=1.01,95%CI=0.59~1.73,I^(2)=30%,P=0.97)。结论SBRT与RFA相比虽未表现出生存获益上的优势,但在HCC局部控制方面表现出较优的效果,尤其是对肿瘤直径>2 cm的患者。 | 杜文婷 何雨 吴越 郁冰心 鲁杨 林元强 战翠萍 金春香 | 2023 | 介入放射学杂志2023，32，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员